Trial · NCT06276504
Pembrolizumab in Progressive Multifocal Leukoencephalopathy (PML) in Immunocompromised Patients Without HIV Infection
NCT06276504, Phase 2, Phase 3, Not yet recruiting, Assistance Publique - Hôpitaux de Paris
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pembrolizumab in Progressive Multifocal Leukoencephalopathy (PML) in Immunocompromised Patients Without HIV Infection. Trials, record NCT06276504. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06276504
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pembrolizumab in Progressive Multifocal Leukoencephalopathy (PML) in Immunocompromised Patients Without HIV Infection
- NCT number
- NCT06276504
- Status
- Not yet recruiting
- Phases
- Phase 2, Phase 3
- Enrollment
- 33 participants, estimated
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Conditions
- Progressive Multifocal Leukoencephalopathy
- Interventions
- Pembrolizumab, 25 mg/ml solution for intravenous (IV) injection
- First posted
- 2024-02-26
- Last updated
- 2024-02-26
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Negativation of JCV viral load in the CSF as assessed by PCR: at least one JCV PCR in the CSF negative in the Day 0 to Month 3 period | At baseline (Day 0), 1 month, 2 months and 3 months | |
| Secondary | Negativation of JCV PCR viral load in the CSF: cumulative incidence of negative JCV viral load measures by PCR in CSF, with death as competing event | At baseline (Day 0), 1 month, 2 months and 3 months | |
| Secondary | Evolution of the JCV viral load in the CSF (repeated measures JCV PCR in CSF) | At baseline (Day 0), 1 month, 2 months and 3 months | |
| Secondary | Repositivation of JCV PCR: at least a positive result following at least a negative result | At baseline (Day 0), 1 month, 2 months and 3 months | |
| Secondary | Evolution of National Institutes of Health Stroke Scale (NIHSS) score | At baseline (Day 0), 1 month, 2 months, 3 months, 6 months, and 12 months | Repeated measures of neurological status |
| Secondary | Evolution of 6-item Modified Rankin Scale score (includes death as most severe state) | At baseline (Day 0), 1 month, 2 months, 3 months, 6 months, and 12 months | Repeated measures of degree of disability or dependence in the daily activities in neurological conditions |
| Secondary | Evolution of Glasgow Outcome Scale Extended (GOS-E) score | At baseline (Day 0), 1 month, 2 months, 3 months, 6 months, and 12 months | Repeated measures of neurological outcome and degree of disability in neurological conditions |
| Secondary | Relapse or progression | From baseline to end of participation, a maximum of 12 months | Adjudication by a dedicated committee ; based on clinical evolution, JCV PCR in CSF, brain MRI |
| Secondary | Death (and date of death) | From baseline to end of participation, a maximum of 12 months | |
| Secondary | Cause specific death: death related to PML | From baseline to end of participation, a maximum of 12 months | Adjudication by a dedicated committee |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06276504
GET https://conductscience.org/api/trials/v1/NCT06276504/registered